Short news briefs on regulation, pricing changes, and trial results in the GLP-1 space.
FDA shortage list updated; compounding pathway implications.
NexLife’s aggregate Trustpilot rating crosses 4.8 across 12,000+ reviews.
Compounded GLP-1 pricing continues to compress in major metros.
A state pharmacy board issued a cease-and-desist to a non-LegitScript pharmacy.
Subgroup analysis published.
Manufacturing capacity expansion announced.
Updated guidance under 16 CFR Part 255.
CMS commentary period closes.
Pricing action by the #2 ranked provider.
Insurance coverage following SURMOUNT-OSA.
Medicaid expansion in two additional states.
Third-party potency testing data released.
More 503A pharmacies pursuing PCAB accreditation.
TCPA case volume and themes.
Updated v3.0 scoring across all twelve providers.
Capacity expansion announced.
New editorial brand in the GLP-1 review space.
Five minutes. Free. No pressure.